Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus
View abstract on PubMed
Summary
This summary is machine-generated.Proton pump inhibitors, NSAIDs/aspirin, and statins may lower esophageal adenocarcinoma risk in Barrett's esophagus patients. NSAID/aspirin and statin use showed significant risk reduction in this study.
Area Of Science
- Gastroenterology
- Oncology
- Pharmacology
Background
- Limited evidence suggests proton pump inhibitors (PPI), nonsteroidal anti-inflammatory drugs (NSAID)/aspirin, and statins may be linked to lower esophageal neoplasia risk.
- The specific impact of these medications on esophageal adenocarcinoma (EAC) risk in patients with Barrett's esophagus (BE) remains unclear.
Purpose Of The Study
- To investigate the association between PPI, NSAID/aspirin, and statin use and the risk of developing esophageal adenocarcinoma (EAC) in patients diagnosed with Barrett's esophagus (BE).
Main Methods
- A nested case-control study was conducted using national Department of Veterans' Affairs computerized databases.
- Patients with BE were identified, and incident EAC cases were matched to controls without EAC.
- Prescription data for PPI, NSAIDs/aspirin, and statins filled between BE diagnosis and EAC diagnosis were analyzed using conditional logistic regression.
Main Results
- In a cohort of 11,823 BE patients, 116 EAC cases and 696 controls were analyzed. PPI use was nearly universal (95% vs 94%).
- NSAID/aspirin prescriptions were associated with a reduced EAC risk (aIDR, 0.64; 95% CI, 0.42-0.97).
- Statin prescriptions also showed a reduced EAC risk (aIDR, 0.55; 95% CI, 0.36-0.86), with greater risk reduction observed with longer duration of use, though uncontrolled confounding is a concern.
Conclusions
- This observational study suggests that NSAID/aspirin and statin therapy may be associated with a reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
- The findings indicate a potential protective effect of these medications, but further research is needed to confirm causality and address confounding factors.